is saxenda a glp 1 agonist Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) now commercially available in the United States Teva brings first generic GLP-1

Nat Med

2) Pancreatitis Concerns Acute pancreatitis, including potentially fatal hemorrhagic and necrotizing types of pancreatitis, has been documented in those taking some GLP-1 RAs

The SURPASS-1 trial investigated the efficacy and safety of the three doses of 5, 10, or 15 mg tirzepatide in drug-nave patients with T2D who were not sufficiently controlled with a lifestyle intervention with diet and exercise versus placebo (70)

In addition, GLP-1 can slow gastric emptying, reduce appetite in patients and thus reduce body mass, control blood pressure, regulate blood lipids and protect cardiovascular function, and has a low risk of hypoglycemia

Diabetes 58 , 975983 (2009)

In the SURMOUNT-1 trial, tirzepatide produced dose-dependent weight reductions, with average losses approaching or exceeding ~20% at higher doses in adults with obesity who did not have diabetes, numbers that markedly exceed historical pharmacotherapy benchmarks